COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.
Advanced Cancer|Ovarian Cancer|Breast Cancer|Lung Cancer|Endometrial Cancer|Ovarian Neoplasm|Triple Negative Breast Cancer|Lung Neoplasm|Neoplasm Malignant|Colo-rectal Cancer
DRUG: COM701|DRUG: COM701 with Opdivo (Nivolumab).
Incidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs)., To evaluate the safety profile of COM701 monotherapy and in combination with nivolumab., DLT evaluation window in the 1st cycle (21 or 28 days).|Determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDFE) (COM701 monotherapy and in combination with nivolumab)., Approximately 2 year.
Incidence of subjects with Anti-COM701 antibody., Immunogenicity of COM701 monotherapy and in combination with nivolumab., Approximately 2 years.|Overall Response Rate as per RECIST v1.1, Preliminary antitumor activity of COM701 in combination with nivolumab., Approximately 2 years.
This Phase 1 study evaluates the safety, tolerability, Pharmacokinetics (PK) and preliminary clinical activity of COM701 an inhibitor of poliovirus receptor related immunoglobulin domain containing (PVRIG) as monotherapy and in combination with nivolumab in subjects with advanced solid tumors. Cohort expansion will be explored evaluating COM701 monotherapy and in combination with nivolumab in subjects with the following select tumor types (Non-Small cell lung cancer (NSCLC), Ovarian, Breast (including Triple negative breast cancer (TNBC) and endometrial cancer. Other tumor types such as CRC-MSS, CRC-KRAS mutant will be enrolled based on emerging clinical activity data.